Additional data were presented suggesting that a single treatment with SB-509 may increase the mobilization of stem cells into a subject’s blood. These circulating stem cells may have implications for the nerve regeneration and nerve and blood vessel growth that have been reported from SB-509 treatment.
In this study subjects received a single treatment in both legs of either placebo (10 subjects) or SB-509 (10 subjects who received 60mg total dose or 30mg per leg). All of the subjects completed six-month follow-up testing. Clinicians observed statistically significant clinical improvements in quantitative sensory testing (QST) which quantifies perception of vibration.
Clinicians also observed a trend for improvement in SB-509 treated patients in a composite measure of nerve health, the modified total neuropathy score or TNS.
Edward Lanphier, president and CEO of Sangamo BioSciences, said: “We continue to be very pleased and impressed by the disease-altering improvements that we have observed in several measurements of nerve health in subjects with mild to moderate diabetic neuropathy treated with SB-509.”